Tabrecta gains full FDA approval for non-small cell lung cancer
The U.S. Food and Drug Administration granted regular approval to capmatinib (Tabrecta) for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a genetic mutation leading to mesenchymal-epithelial ...
Aug 15, 2022
0
6